Validity of commercial serologic tests for dermatomyositis still questionable

“The testing in research laboratories is not widely available and the results are often delayed by weeks to months.”

Recent psoriasis pathophysiology insights carry treatment implications

“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”

Deucravacitinib offers biologic-like psoriasis efficacy in oral form

Novel anti-inflammatory mechanism involves selective TYK2 inhibition.

International expert group agrees on redefining psoriasis severity

“What we came up with is a very sensible approach to defining whether patients should get either topical or systemic therapy.”

The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis

“The guidelines don’t give full credit to the anti–IL-17 agents.”

COVID-19 risks in rheumatic disease remain unclear

Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more encouraging news for people living with rheumatic disease.

Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring

For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or systemic agents.”

Dr. Brian Mandell gives his take on ACR’s newest gout guideline

New guideline articulates a broad approach to treatment that needs to be tailored to individual patients.

Reassuring rheumatic disease patients on value of bisphosphonates

Dr. Marcy B. Bolster addresses common patient concerns about bisphosphonate use.

Strategic approach mitigates impact of antidrug antibodies in patients with rheumatic diseases

Consider dose escalation and adding an immunomodulator to overcome the impact of antidrug antibodies in rheumatic disease patients.

Pages